New York, March 2, 2026, 15:46 (EST) — Regular session
UnitedHealth Group Incorporated (UNH) traded mostly flat Monday, with shares inching up roughly 0.2% to $293.71 as the latest round of Medicare regulation risk in managed care kept investors on alert.
This context is crucial: Medicare Advantage, the private alternative to traditional U.S. Medicare, now drives significant profits for major insurers. The “risk adjustment” process—tied to diagnosis codes and used to reimburse insurers extra for sicker enrollees—means even minor compliance tweaks can have a real financial impact.
UnitedHealth, in its annual report filed Monday, noted that Medicare Advantage and Medicare Part D premiums remain open to retroactive adjustments under the Centers for Medicare & Medicaid Services’ risk-adjustment process, with payments subject to audit and government review. The company disclosed that certain local plans are under risk adjustment data validation (RADV) audits—those reviews check whether diagnoses supporting payments are actually documented in medical records. These audits can lead to payment clawbacks, fines, or other penalties. UnitedHealthcare ended 2025 with around 8.4 million Medicare Advantage members, according to the filing.
Renewed scrutiny kicked in after Elevance Health revealed that CMS plans to hit the company with sanctions, which would block new enrollment in its Medicare Advantage prescription drug plans. Barclays’ Andrew Mok flagged the development as “a negative regulatory signal.” He also noted the enrollment freeze likely won’t dent near-term earnings. In response, Elevance said it’s reviewing the letter, plans to work with CMS, and clarified that any enrollment suspension leaves existing members untouched. Reuters
Elevance slid roughly 9%. Humana dropped 2.5%. Cigna edged lower—just a fractional move there. UnitedHealth, by contrast, was among the only major managed-care stocks hovering near unchanged.
UnitedHealth is shaking up its accounting ranks. Dennis Stankiewicz steps in as chief accounting officer starting March 2, while Thomas Roos shifts over to take the CFO role at Optum Insight.
UnitedHealth’s Heather Cianfrocco is stepping down after 24 years with the company. “I am leaving with so much pride” in the team’s achievements, she posted on LinkedIn, Healthcare Dive reported. Healthcare Dive
The stock barely budged after January’s abrupt shake-up. UnitedHealth had flagged its first revenue drop in decades, and the federal Medicare agency followed with a nearly flat proposed 2027 rate update for Medicare Advantage plans. That jolt dragged the sector down and put investors on edge about rate and audit headlines.
The larger worry for UnitedHealth? That stricter enforcement ends up as the norm. In January, a Senate committee report said the company had used aggressive risk-adjustment coding to inflate Medicare payments, a claim UnitedHealth pushed back on, insisting it follows all relevant requirements.
Focus is turning to whether the Elevance case turns into a broader industry story. Elevance disclosed in its filing that it needs to submit a written rebuttal by March 10. Unless the Centers for Medicare & Medicaid Services is convinced the problems are resolved, sanctions will take effect on March 31.
